Last 12 months
Inside the activity.
11 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 3 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 3 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2022 Filed May 20, 2022 20:08 UTC |
Jayne David R.W.Director
|
GrantRestricted Stock Unit · Derivative | 8,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-015031 · wf-form4_165307729475114.xml · derivative · entry 1 Jayne David R.W. · CIK 0001838242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,733 Underlying: Common Shares · 8,733 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. Read SEC document |
| May 18, 2022 Filed Jul 11, 2022 10:16 UTC Amendment |
Jayne David R.W.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0001628280-22-018767 · wf-form4a_165753457810786.xml · derivative · entry 2 Jayne David R.W. · CIK 0001838242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. Read SEC document |
| May 18, 2022 Filed Jul 11, 2022 10:16 UTC Amendment |
Jayne David R.W.Director
|
Exercise / conversionCommon Stock | 10,000 | $3.62 | $36,200.00 |
DisclosureSEC source: 0001628280-22-018767 · wf-form4a_165753457810786.xml · nonDerivative · entry 1 Jayne David R.W. · CIK 0001838242 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:05 UTC |
MacKay-Dunn R. HectorDirector
|
PurchaseCommon Stock | 5,000 | $11.00 | $54,985.00 |
DisclosureSEC source: 0001628280-22-005882 · wf-form4_164703270263952.xml · nonDerivative · entry 1 MacKay-Dunn R. Hector · CIK 0001838521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:06 UTC |
MILNE GEORGE M JRDirector
|
PurchaseCommon Stock | 5,000 | $10.82 | $54,100.00 |
DisclosureSEC source: 0001628280-22-005381 · wf-form4_164677357726147.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.81 to $10.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Greenleaf PeterDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 534,188 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · derivative · entry 4 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,188 Underlying: Common Stock · 534,188 shares Expires 2032-03-02 F5 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Greenleaf PeterDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 312,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · derivative · entry 3 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,240 Underlying: Common Shares · 312,240 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Greenleaf PeterDirector · Chief Executive Officer
|
SaleCommon Stock | 9,068 | $12.01 | $108,906.68 |
DisclosureSEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · nonDerivative · entry 2 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,967 F3 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Greenleaf PeterDirector · Chief Executive Officer
|
GrantCommon Stock | 28,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005123 · wf-form4_164642827067393.xml · nonDerivative · entry 1 Greenleaf Peter · CIK 0001363683 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,035 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 282 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Robertson Stephen P.EVP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005121 · wf-form4_164642825231972.xml · derivative · entry 3 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Robertson Stephen P.EVP, General Counsel
|
GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005121 · wf-form4_164642825231972.xml · derivative · entry 2 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Robertson Stephen P.EVP, General Counsel
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005121 · wf-form4_164642825231972.xml · nonDerivative · entry 1 Robertson Stephen P. · CIK 0001837798 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,682 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 462 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC |
Martin Michael RobertChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 106,838 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · derivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,838 Underlying: Common Stock · 106,838 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC |
Martin Michael RobertChief Business Officer
|
GrantRestricted Stock Unit · Derivative | 62,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · derivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,448 Underlying: Common Shares · 62,448 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC |
Martin Michael RobertChief Business Officer
|
SaleCommon Stock | 4,849 | $12.01 | $58,236.49 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,512 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC |
Martin Michael RobertChief Business Officer
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,361 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Donley Matthew MaxwellEx VP, Intern'l Operations
|
GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · derivative · entry 4 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F5 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Donley Matthew MaxwellEx VP, Intern'l Operations
|
GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · derivative · entry 3 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Donley Matthew MaxwellEx VP, Intern'l Operations
|
SaleCommon Stock | 3,052 | $12.01 | $36,654.52 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · nonDerivative · entry 2 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,224 F3 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Donley Matthew MaxwellEx VP, Intern'l Operations
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005129 · wf-form4_164642834162109.xml · nonDerivative · entry 1 Donley Matthew Maxwell · CIK 0001636642 · Ex VP, Intern'l Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,276 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 876 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Miller Joseph MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · derivative · entry 4 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F5 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Miller Joseph MChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · derivative · entry 3 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F4 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Miller Joseph MChief Financial Officer
|
SaleCommon Stock | 3,060 | $12.01 | $36,750.60 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · nonDerivative · entry 2 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,610 F3 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:12 UTC |
Miller Joseph MChief Financial Officer
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005127 · wf-form4_164642831364007.xml · nonDerivative · entry 1 Miller Joseph M · CIK 0001746372 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,670 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. F2 · balance_after: Includes 170 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Colao MassimilanoChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 178,063 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · derivative · entry 4 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,063 Underlying: Common Stock · 178,063 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Colao MassimilanoChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 104,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · derivative · entry 3 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,080 Underlying: Common Shares · 104,080 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Colao MassimilanoChief Commercial Officer
|
SaleCommon Stock | 3,205 | $12.01 | $38,492.05 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · nonDerivative · entry 2 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,495 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:11 UTC |
Colao MassimilanoChief Commercial Officer
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005124 · wf-form4_164642829060367.xml · nonDerivative · entry 1 Colao Massimilano · CIK 0001837645 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,700 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Solomons NeilChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 124,644 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · derivative · entry 4 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,644 Underlying: Common Stock · 124,644 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Solomons NeilChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 72,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · derivative · entry 3 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,856 Underlying: Common Shares · 72,856 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Solomons NeilChief Medical Officer
|
SaleCommon Stock | 4,846 | $12.01 | $58,200.46 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · nonDerivative · entry 2 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,953 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Solomons NeilChief Medical Officer
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005119 · wf-form4_164642821472438.xml · nonDerivative · entry 1 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,799 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Huizinga Robert BindertEVP of Research
|
GrantStock Option (right to buy) · Derivative | 106,838 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · derivative · entry 4 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,838 Underlying: Common Stock · 106,838 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Huizinga Robert BindertEVP of Research
|
GrantRestricted Stock Unit · Derivative | 62,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · derivative · entry 3 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,448 Underlying: Common Shares · 62,448 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Huizinga Robert BindertEVP of Research
|
SaleCommon Stock | 4,849 | $12.01 | $58,236.49 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · nonDerivative · entry 2 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,379 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC |
Huizinga Robert BindertEVP of Research
|
GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,228 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 16:17 UTC |
Hagan Joseph PDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001628280-22-000182 · wf-form4_164133098196321.xml · derivative · entry 4 Hagan Joseph P · CIK 0001465278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 40,000 shares Expires 2028-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 16:17 UTC |
Hagan Joseph PDirector
|
SaleCommon Stock | 634 | $23.29 | $14,765.86 |
DisclosureSEC source: 0001628280-22-000182 · wf-form4_164133098196321.xml · nonDerivative · entry 3 Hagan Joseph P · CIK 0001465278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 16:17 UTC |
Hagan Joseph PDirector
|
SaleCommon Stock | 39,366 | $22.58 | $888,884.28 |
DisclosureSEC source: 0001628280-22-000182 · wf-form4_164133098196321.xml · nonDerivative · entry 2 Hagan Joseph P · CIK 0001465278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,134 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $22.27 to $23.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 16:17 UTC |
Hagan Joseph PDirector
|
Exercise / conversionCommon Stock | 40,000 | $5.08 | $203,200.00 |
DisclosureSEC source: 0001628280-22-000182 · wf-form4_164133098196321.xml · nonDerivative · entry 1 Hagan Joseph P · CIK 0001465278 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 21:09 UTC |
Leversage JillDirector
|
PurchaseCommon Stock | 1,600 | $20.04 | $32,064.00 |
DisclosureSEC source: 0001628280-21-025130 · wf-form4_163960257768858.xml · nonDerivative · entry 1 Leversage Jill · CIK 0001837374 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $20.02 to $20.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC |
Martin Michael RobertChief Business Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 29,000 | $0.00 Strike: $18.38 | $0.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · derivative · entry 7 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,900 Underlying: Common Stock · 29,000 shares Expires 2030-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC |
Martin Michael RobertChief Business Officer
|
SaleCommon Shares | 11,000 | $29.50 | $324,500.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 6 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC |
Martin Michael RobertChief Business Officer
|
SaleCommon Stock | 29,000 | $28.82 | $835,780.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 5 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.60 to $29.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC |
Martin Michael RobertChief Business Officer
|
Exercise / conversionCommon Stock | 29,000 | $18.38 | $533,020.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:13 UTC |
Solomons NeilChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · derivative · entry 10 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F8 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:13 UTC |
Solomons NeilChief Medical Officer
|
SaleCommon Stock | 100,000 | $28.89 | $2,889,000.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 7 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.50 to $29.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:13 UTC |
Solomons NeilChief Medical Officer
|
Exercise / conversionCommon Stock | 100,000 | $5.30 | $530,000.00 |
DisclosureSEC source: 0001628280-21-023153 · wf-form4_163675158142693.xml · nonDerivative · entry 6 Solomons Neil · CIK 0001837720 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:18 UTC |
Martin Michael RobertChief Business Officer
|
SaleCommon Shares | 10,000 | $30.55 | $305,500.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.30 to $30.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:18 UTC |
Martin Michael RobertChief Business Officer
|
SaleCommon Shares | 50,000 | $31.26 | $1,563,000.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.00 to $31.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.